Business Description
Mirati Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US60468T1051
Description
Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 19.44 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 8.66 | |||||
| Beneish M-Score | -0.97 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 35.4 | |||||
| 3-Year EBITDA Growth Rate | -31.5 | |||||
| 3-Year EPS without NRI Growth Rate | -32.3 | |||||
| 3-Year FCF Growth Rate | -36.9 | |||||
| 3-Year Book Growth Rate | 21.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.22 | |||||
| 9-Day RSI | 46.68 | |||||
| 14-Day RSI | 54.98 | |||||
| 6-1 Month Momentum % | 88.25 | |||||
| 12-1 Month Momentum % | 23.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.54 | |||||
| Quick Ratio | 7.4 | |||||
| Cash Ratio | 7.11 | |||||
| Days Inventory | 741.92 | |||||
| Days Sales Outstanding | 77.09 | |||||
| Days Payable | 2514.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.5 | |||||
| Shareholder Yield % | -0.06 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.51 | |||||
| Operating Margin % | -2002.75 | |||||
| Net Margin % | -1900.65 | |||||
| FCF Margin % | -1560.4 | |||||
| ROE % | -77.82 | |||||
| ROA % | -64.99 | |||||
| ROIC % | -580.14 | |||||
| 3-Year ROIIC % | -429.71 | |||||
| ROC (Joel Greenblatt) % | -1446.43 | |||||
| ROCE % | -78.11 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 93.62 | |||||
| PB Ratio | 4.35 | |||||
| Price-to-Tangible-Book | 4.41 | |||||
| EV-to-EBIT | -4.17 | |||||
| EV-to-EBITDA | -4.2 | |||||
| EV-to-Revenue | 83.57 | |||||
| EV-to-Forward-Revenue | 27.31 | |||||
| EV-to-FCF | -5.36 | |||||
| Price-to-Net-Current-Asset-Value | 4.83 | |||||
| Price-to-Net-Cash | 5.19 | |||||
| Earnings Yield (Greenblatt) % | -23.98 | |||||
| FCF Yield % | -14.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MRTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mirati Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 38.191 | ||
| EPS (TTM) ($) | -12.22 | ||
| Beta | 0 | ||
| Volatility % | 59.25 | ||
| 14-Day RSI | 54.98 | ||
| 14-Day ATR ($) | 0.375805 | ||
| 20-Day SMA ($) | 58.92975 | ||
| 12-1 Month Momentum % | 23.02 | ||
| 52-Week Range ($) | 27.3 - 64.41 | ||
| Shares Outstanding (Mil) | 70.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mirati Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mirati Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mirati Therapeutics Inc Frequently Asked Questions
What is Mirati Therapeutics Inc(MRTX)'s stock price today?
The current price of MRTX is $58.70. The 52 week high of MRTX is $64.41 and 52 week low is $27.30.
When is next earnings date of Mirati Therapeutics Inc(MRTX)?
The next earnings date of Mirati Therapeutics Inc(MRTX) is 2025-02-28 Est..
Does Mirati Therapeutics Inc(MRTX) pay dividends? If so, how much?
Mirati Therapeutics Inc(MRTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers